Status:

COMPLETED

Virtual Exercise for Multiple Myeloma

Lead Sponsor:

University of Alberta

Conditions:

Multiple Myeloma

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The primary objective of this pilot study is to determine the safety and feasibility a 12-week virtually supported home-based aerobic and resistance exercise program progressing cancer survivors with ...

Detailed Description

Multiple myeloma (MM), a cancer of the plasma cells in bone marrow, is associated with osteolytic bone destruction, leading to deformities, chronic pain, reduced mobility and functioning, fatigue, and...

Eligibility Criteria

Inclusion

  • 18 years of age and older
  • Diagnosis of multiple myeloma
  • In one of the following three treatment categories:
  • Transplant ineligible patients, currently in first line treatment
  • Transplant eligible patients, sufficiently recovered from transplantation (\>3 months following transplantation)
  • Patients with relapsed/recurrent myeloma with either 1-3 prior lines of treatment or 4+ prior lines
  • Able to provide informed written consent in English
  • Approved for physical activity participation by their oncologist and cleared for physical activity by the Certified Exercise Physiologist on the PAR-Q+

Exclusion

  • Unstable cardiac/metabolic condition that would be deemed unsafe to exercise
  • Severe anemia
  • Spinal instability requiring surgical intervention
  • AL amyloidosis, solitary plasmacytoma, or Waldenstrom macroglobulinemia
  • Too frail to participate in home exercise, as determine by baseline physical assessment (i.e., unable to complete a single sit-to-stand or balance on one foot for ≥ 3 seconds).
  • Inability to provide consent
  • Inability to commit to, and/or comply with the intervention due to personal reasons (e.g. vacation planned during the intervention period)

Key Trial Info

Start Date :

September 15 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 31 2021

Estimated Enrollment :

31 Patients enrolled

Trial Details

Trial ID

NCT04484714

Start Date

September 15 2020

End Date

August 31 2021

Last Update

September 17 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Alberta/ Cross Cancer Institute

Edmonton, Alberta, Canada, T6G 2G4